Charles Bair

Partner
Full contact info

Experience

Bristol Myers Squibb to Acquire Turning Point Therapeutics for $4.1 Billion

June 4, 2022

Cooley is advising Turning Point Therapeutics, a leading precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb. Lawyers Barbara Borden, Rowook Park, Charles Bair, Lindsey O’Crump, Vivian Tsai and Melissa Meza are leading the Cooley team advising Turning Point Therapeutics.

Read more

Related contacts

Barbara Borden
Partner, San Diego
Rowook Park
Partner, San Diego
Charles Bair
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Melissa Meza
Associate, San Diego
Alessandra Murata
Partner, Palo Alto
Ross Eberly
Partner, Los Angeles Santa Monica
Koji Fukumura
Partner, San Diego
Phil Mitchell
Partner, New York
David Navetta
Partner, Colorado
Todd Gluth
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Matthew D. Silverman
Special Counsel, San Diego
Stella Sarma
Special Counsel, Brussels
Christine Graham
Special Counsel, London
Brendan Haberle
Associate, San Diego
Megan Drill
Associate, San Diego
Heidi E. Wang
Associate, San Diego
Eileen Leman
Associate, Los Angeles Downtown
Daniel Gillon
Associate, San Diego
Wade Andrews
Associate, San Diego
Amanda Pacheco
Associate, Palo Alto
Jennifer Shanley
Special Counsel, New York
Daniel Lac
Associate, San Diego

Related Practices & Industries

Kronos Bio – $288 million IPO

October 8, 2020

Cooley advised Kronos Bio on its $287.5 million initial public offering of 15,131,579 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Kronos Bio, whose securities now trade on the Nasdaq Global Select Market under the symbol KRON, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. Partners Charles Bair, Charlie Kim and Chad Mills led the Cooley team.

Related contacts

Charles Bair
Partner, San Diego
Chadwick Mills
Partner, San Francisco
Asa Henin
Special Counsel, San Diego
Brett Dovman
Associate, San Diego
Stephanie Leigh
Paralegal Specialist, San Diego
Kate Walther
Paralegal Specialist, San Diego

Related Practices & Industries

Turning Point Therapeutics - $192 Million IPO

April 17, 2019

Cooley advised Turning Point Therapeutics on its $191.5 million initial public offering of 10,637,500 shares of common stock. Turning Point Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol “TPTX,” is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Partners Charles Bair and Karen Anderson led the Cooley team.

Related contacts

Charles Bair
Partner, San Diego
Asa Henin
Special Counsel, San Diego
Terren O'Connor
Associate, San Diego

Related Practices & Industries

Allogene Therapeutics – $372.6 Million IPO

October 10, 2018

Cooley advised Allogene Therapeutics, Inc. on its $372.6 million initial public offering of 20,700,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 2,700,000 shares. Partners Charles Bair and Charlie Kim led the Cooley team advising Allogene Therapeutics.

Goldman Sachs, J.P. Morgan Securities, Cowen and Jefferies acted as joint book-running managers for the offering.

Allogene Therapeutics is a clinical stage immuno-oncology company developing allogeneic T cell therapies for the treatment of cancer. The company’s shares now trade on the Nasdaq Global Select Market under the symbol “ALLO.”

Related contacts

Charles Bair
Partner, San Diego
Charlie Kim
Partner, San Diego
Asa Henin
Special Counsel, San Diego
Carlos Ramirez
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Madhuri Roy
Partner, Palo Alto

Related Practices & Industries

Cidara Completes Initial Public Offering

April 24, 2015

Cooley advised Cidara Therapeutics on its initial public offering. Cidara, headquartered in San Diego, is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. The company trades on the Nasdaq Global Market under the symbol "CDTX."

Related contacts

Charles Bair
Partner, San Diego
Charlie Kim
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York

Related Practices & Industries

View more

Memberships & affiliations

American Bar Association

San Diego County Bar Association

State Bar of California